from The American Heritage® Dictionary of the English Language, 4th Edition
- n. An enzyme that catalyzes the hydrolysis of peptides into amino acids.
from Wiktionary, Creative Commons Attribution/Share-Alike License
- n. Any enzyme that catalyzes the hydrolysis of peptides into amino acids; a protease
from WordNet 3.0 Copyright 2006 by Princeton University. All rights reserved.
- n. any enzyme that catalyzes the splitting of proteins into smaller peptide fractions and amino acids by a process known as proteolysis
Sorry, no etymologies found.
CD26/dipeptidyl peptidase IV: A regulator of immune function and a potential molecular target for therapy.
University, who worked at that time on translocation of proteins across the endoplasmic reticulum (ER) membrane, a process that involves cleavage of the leader peptide by signal peptidase, to Jeffrey Roberts in Cornell University who worked on E. coli RecA protein-directed cleavage of phage l repressor and its requirement for polynucleotide, and to Harvey Lodish at the M.I.T. who worked, among other subjects, on processing of viral polyproteins.
Recent comments by Dr. Daniel Drucker, a professor at the University of Toronto and leader in diabetes and endocrinology, suggested dipeptidyl peptidase agents such as those being developed by Merck and Novartis have potential as effective second-line treatments for type 2 diabetes, according to Morgan Stanley.
It was not until the mid-1990s that researchers saw another way: An enzyme called dipeptidyl peptidase four DPP4 broke down GLP, and by inhibiting it, researchers could boost GLP levels in the body.
Those results, as well as data on a class of drugs known as dipeptidyl peptidase IV inhibitors DPIV, could provide a catalyst for OSI shares, the Wachovia analyst said.
Both pills work by inhibiting an enzyme called dipeptidyl peptidase 4 DPP-IV, which breaks down hormones that help control blood sugar.
Some of the preexisting protein translocation apparatus of the endosymbiont appears to have been commandeered, including molecular chaperones, the signal peptidase, and some components of the protein-targeting machinery.
Osborne, who expects FDA approval of Novartis' Galvus in the first quarter, is one of a handful of analysts who believe Byetta will see significant competition from a new class of diabetes treatments known as dipeptidyl peptidase inhibitors.
A peptidase enzyme capable of acting on any peptide linkage in a peptide chain.
We also now have a library of dipeptidyl-peptidase IV DPP-4 inhibitors that we